Sugi Predict

Sugi Predict / Compounds / SCHEMBL719657

SCHEMBL719657

SCHEMBL719657

CCOC(=O)c1ccc(Br)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ GABRA1 P14867 1/20 0.51
▸ GABRB1 P18505 1/20 0.51
▸ GABRA3 P34903 1/20 0.51
▸ GABRB2 P47870 1/20 0.51
▸ CA12 O43570 2/20 0.50
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ CA7 P43166 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ CA14 Q9ULX7 2/20 0.50
▸ TSHR P16473 1/20 0.50
▸ LMNA P02545 2/20 0.49
▸ ALOX5 P09917 4/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ PKM P14618 1/20 0.46
▸ PDE3B Q13370 1/20 0.46
▸ PDE3A Q14432 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31426389 0.98 DGAT1 (0.53) DGAT1ALDH1A1SMN1; SMN2GABRA1GABRB1
SCHEMBL31621322 0.91 DGAT1 (0.50) DGAT1ALDH1A1SMN1; SMN2GABRA1GABRB1
SCHEMBL961701 0.87 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3
SCHEMBL30622008 0.84 ATM (0.56) DGAT1ALDH1A1SMN1; SMN2TSHRLMNA
SCHEMBL234030 0.84 TSHR (0.60) ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3
SCHEMBL2573892 0.83 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3
SCHEMBL5273471 0.83 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3
SCHEMBL367075 0.83 TSHR (0.57) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL8158480 0.83 CA12 (0.57) ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3
SCHEMBL289045 0.83 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2GABRA1GABRB1GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955313-B Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2025-06-17 — — CN claimed
CN-118955313-A Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2024-11-15 — — CN claimed
CN-108947782-A A kind of bromine fluorine Multi substituted benzenes formaldehyde derivatives and preparation method 上海罕道医药科技有限公司 2018-12-07 — — CN claimed
WO-2026031298-A1 METHOD FOR SYNTHESIZING KEY INTERMEDIATE OF ENZALUTAMIDE 安徽峆一药业股份有限公司 2026-02-12 — — WO disclosed
CN-118955313-B Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2025-06-17 — — CN disclosed
CN-118955313-B Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2025-06-17 — — CN disclosed
US-20250051329-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC (US) 2025-02-13 — — US disclosed
US-12220419-B2 BCL-2 inhibitors NEWAVE PHARMACEUTICAL INC. (US) 2025-02-11 — — US disclosed
US-12145949-B2 Cyclic supported catalysts Universite Paris-Saclay (FR) 2024-11-19 — — US disclosed
CN-118955313-A Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2024-11-15 — — CN disclosed
CN-118955313-A Synthesis method of enzalutamide key intermediate 安徽峆一药业股份有限公司 2024-11-15 — — CN disclosed
US-20070129416-A1 4,4,5,5, Tetrasubstituted imidazolines DING QINGJIE 2007-06-07 — — US disclosed
WO-2007002563-A1 IMIDAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 — — WO disclosed
WO-2007002563-A1 IMIDAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 — — WO disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 — — WO disclosed
US-7074801-B1 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof EISAI CO., LTD. (JP) 2006-07-11 — — US disclosed
WO-2006034491-A2 PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2006-03-30 — — WO disclosed
WO-2006034512-A2 PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2006-03-30 — — WO disclosed
WO-2006034512-A2 PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2006-03-30 — — WO disclosed
EP-1382603-A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-01-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129416-A1 4,4,5,5, Tetrasubstituted imidazolines RPS4X, RPS4Y1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 DGAT1 4611/4885ALDH1A1 1342/4885SMN1; SMN2 1035/4885
US-12220419-B2 BCL-2 inhibitors BCL2L10, BCL2, BCL2L11 DGAT1 4227/4885ALDH1A1 3743/4885SMN1; SMN2 1293/4885
US-12145949-B2 Cyclic supported catalysts CYCS, CALU, CALD1 DGAT1 4472/4885ALDH1A1 2512/4885SMN1; SMN2 4725/4885
US-20250051329-A1 BCL-2 INHIBITORS BCL2L1, BCL2, BCL2A1 DGAT1 2751/4885ALDH1A1 2239/4885SMN1; SMN2 1074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.